AstraZeneca's NIAGARA Phase 3 Trial Of Imfinzi (Durvalumab) Plus Chemotherapy Showed Statistically Significant And Clinically Meaningful Improvement In Event-free Survival And Overall Survival Vs Neoadjuvant Chemotherapy In Muscle-invasive Bladder Cancer
AstraZeneca's NIAGARA Phase 3 Trial Of Imfinzi (Durvalumab) Plus Chemotherapy Showed Statistically Significant And Clinically Meaningful Improvement In Event-free Survival And Overall Survival Vs Neoadjuvant Chemotherapy In Muscle-invasive Bladder Cancer
阿斯利康的NIAGARA第3階段試驗顯示，Imfinzi（Durvalumab）化療聯合方案較新輔助化療在侵襲性膀胱癌中的事件自由生存期和總生存期均有明顯和臨床意義的改善。
AstraZeneca's NIAGARA Phase 3 Trial Of Imfinzi (Durvalumab) Plus Chemotherapy Showed Statistically Significant And Clinically Meaningful Improvement In Event-free Survival And Overall Survival Vs Neoadjuvant Chemotherapy In Muscle-invasive Bladder Cancer
阿斯利康的NIAGARA第3階段試驗顯示，Imfinzi（Durvalumab）化療聯合方案較新輔助化療在侵襲性膀胱癌中的事件自由生存期和總生存期均有明顯和臨床意義的改善。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。